Canary App for Alzheimer's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests an app that analyzes voice patterns to help diagnose mild cognitive impairment (MCI) and Alzheimer's disease. The goal is to determine if the app's diagnosis aligns with doctors' assessments for these conditions. Participants include those with MCI, those with Alzheimer's, and healthy volunteers without these conditions. Individuals diagnosed with MCI or Alzheimer's who speak English fluently and do not have voice-affecting medical conditions may qualify for this trial. As an unphased study, this trial offers a unique opportunity to contribute to innovative research that could revolutionize early diagnosis methods for cognitive conditions.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on voice analysis, so it's unlikely that your medications would be affected, but you should confirm with the trial organizers.
What prior data suggests that the Canary App is safe for diagnosing MCI and Alzheimer's disease?
Research has shown that the Canary Application can use voice analysis to detect early signs of cognitive issues like Alzheimer's and mild cognitive impairment (MCI). The app examines vocal biomarkers, which are small changes in voice that might indicate cognitive decline.
In terms of safety, the Canary Application is non-invasive. It involves no procedures or medications that could cause side effects. As a software tool, it has not been associated with any negative effects. The app only uses voice recordings, making it easy and comfortable for users.
Overall, for those considering participation, the app itself poses no physical risk. It diagnoses by listening to the voice, not by interacting with the body.12345Why are researchers excited about this trial?
Researchers are excited about the Canary App for Alzheimer's Disease because it represents a novel approach to managing cognitive impairment through technology. Unlike traditional treatments, which often involve medications like cholinesterase inhibitors and memantine, the Canary App leverages digital tools to monitor and potentially improve cognitive functions. This app offers a non-invasive, accessible, and user-friendly way to engage patients in their care, potentially providing real-time data and personalized interventions. By focusing on early intervention and continuous monitoring, the app could transform how mild cognitive impairment and Alzheimer's are managed, making it a groundbreaking addition to existing treatment options.
What evidence suggests that the Canary App is effective for diagnosing mild cognitive impairment and Alzheimer's disease?
Research shows that the Canary App, used by participants in this trial, can detect mild cognitive impairment (MCI) by analyzing voice patterns. Studies have found that voice data can serve as markers to help identify MCI early, offering an easy and affordable method. For Alzheimer's disease, Canary's AI model demonstrated 96% accuracy in detecting the condition through simple conversation. These findings suggest that the app could effectively spot early signs of MCI and Alzheimer's by examining speech patterns. This technology could enable earlier detection, allowing for timely treatment. Participants in this trial will be grouped into different arms, including those with MCI, those with Alzheimer's, and healthy volunteers, to evaluate the app's effectiveness across these groups.14678
Who Is on the Research Team?
Sakshi Jain, MD
Principal Investigator
Hackensack Meridian Health
Are You a Good Fit for This Trial?
This trial is for individuals who have been diagnosed with mild cognitive impairment (MCI) or Alzheimer's disease (AD). The study aims to include a diverse group of participants to ensure the application can be used widely.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Assessment
Participants' voice characteristics are analyzed using the CANARY application to diagnose MCI and Alzheimer's disease
Follow-up
Participants are monitored for accuracy of the application diagnosis compared to clinical diagnosis
What Are the Treatments Tested in This Trial?
Interventions
- The Canary Application
Trial Overview
The study is testing 'The Canary Application,' which uses voice analysis to diagnose MCI and AD. It will compare the app's diagnostic results with those from clinicians to check its accuracy.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
Patients with a mild congitive impairment
Patients with an Alzheimer's Disease diagnosis
Patients without a diagnosis of MCI or Alzheimer's, or other types of dementia
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hackensack Meridian Health
Lead Sponsor
Canary Speech Inc.
Collaborator
Citations
Canary Speech - How It Works
Screen for responses to treatment and monitor patient outcomes using Canary's proprietary data modeling. Predictive health. Monitor wellness over time using ...
2.
insights.citeline.com
insights.citeline.com/MT154459/Canary-Speechs-Voice-AI-Can-Help-Detect-Alzheimers-With-40-Second-Conversation/Canary Speech's Voice AI Can Help Detect Alzheimer's With ...
The recordings were used to create a first diagnostic model for the disease with 96% accuracy in identifying Alzheimer's. Growing Body Of ...
3.
clinicaltrials.gov
clinicaltrials.gov/study/NCT06994767?term=AREA%5BBasicSearch%5D(AREA%5BBasicSearch%5D(CANARY))&rank=2NCT06994767 | Speech-derived Digital Biomarkers Study
The CANARY application will use clinically validated survey instruments and voice recordings to analyze the data and determine the patient's MCI/ Alzheimer's ...
Collaboration with Canary Speech To Target ...
“Canary AI-driven Speech technology will provide invaluable data to help us tailor our therapies more effectively and improve outcomes for ...
The Financial and Clinical Power of Detecting Cognitive ...
Through AI-driven speech analytics, Canary Speech identifies subtle vocal biomarkers indicating cognitive decline, often long before traditional ...
Canary Cognitive
Our AI-powered models are designed to detect early signs of MCI, Alzheimer's, Huntington's, and Parkinson's Disease using vocal biomarkers. We offer real-time ...
7.
canaryspeech.com
canaryspeech.com/blog/canary-speechs-voice-ai-can-help-detect-alzheimers-with-40-second-conversation/Canary Speech's Voice AI Can Help Detect Alzheimer's ...
Canary Speech's ongoing efforts to utilize voice analysis in diagnosing Alzheimer's disease and mild cognitive impairment suggest that AI-driven speech analysis
Should artificial intelligence be used in conjunction with ...
The results show the model was able to predict with high accuracy the 4-year rate of global cognitive and memory decline in sporadic AD individuals (Franzmeier ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.